ReviewNature reviews. Clinical oncology2018
Epigenome-based cancer risk prediction: rationale, opportunities and challenges.
Review in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 110 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gastric Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Epigenetic Ageing and Breast Cancer Risk: A Systematic Review.Cancer medicine · 2024Pooled it
- OPCML Methylation and the Risk of Ovarian Cancer: A Meta and Bioinformatics Analysis.Frontiers in cell and developmental biology · 2021Pooled it
- Discovery and validation of methylation signatures in circulating cell-free DNA for early detection of esophageal cancer: a case-control study.BMC medicine · 2021Trial
- Liquid biopsy-based multi-omics approach for early detection of hepatocellular carcinoma (ASCEND-Hep): a multiphase prospective development and validation study.BMC medicine · 2026Article
- Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.NPJ breast cancer · 2026Review
- Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction.BMC medicine · 2026Article
- Pan-cancer differentially methylated regions are promising biomarkers for non-invasive diagnosis in multiple cancers.iScience · 2026Article
- The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer.International journal of cancer · 2026Article
- Comprehensive molecular characterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers.Communications medicine · 2026Article
- Liquid biopsy in lung cancer screening: rationale, progress, opportunities and challenges.Clinical and experimental medicine · 2025Review
- Review
- Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation.Science bulletin · 2025Review
- Role of multi-omics in aquaculture genetics and breeding: current status and future perspective.Science China. Life sciences · 2025Review
- Review
- Cost-Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Constitutional Epimutations: From Rare Events Toward Major Cancer Risk Factors?JCO precision oncology · 2025Review
- Highly Sensitive and Specific Lateral Flow Detection for DNA Methylation Based on GIaI-Mediated Specific-Terminal-Mediated Polymerase Chain Reaction.Micromachines · 2025Article
- Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Transforming Cancer Care: Genomic Profiling, AI, and Next-Generation Drug Delivery Systems.Current genomics · 2025Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of cancer is continuing to rise and risk-tailored early diagnostic and/or primary prevention strategies are urgently required. The ideal risk-predictive test should: integrate the effects of both genetic and nongenetic factors and aim to capture these effects using an approach that is both biologically stable and technically reproducible; derive a score from easily accessible biological samples that acts as a surrogate for the organ in question; and enable the effectiveness of risk-reducing measures to be monitored. Substantial evidence has accumulated suggesting that the epigenome and, in particular, DNA methylation-based tests meet all of these requirements. However, the development and implementation of DNA methylation-based risk-prediction tests poses considerable challenges. In particular, the cell type specificity of DNA methylation and the extensive cellular heterogeneity of the easily accessible surrogate cells that might contain information relevant to less accessible tissues necessitates the use of novel methods in order to account for these confounding issues. Furthermore, the engagement of the scientific community with health-care professionals, policymakers and the public is required in order to identify and address the organizational, ethical, legal, social and economic challenges associated with the routine use of epigenetic testing.
Indexed as
Identifiers
29485132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.